title: Genetics and immunology: reinvigorated.
abstract: Immune checkpoint blockade therapy is changing oncology by improving the outcome of patients with advanced malignancies. Our research has revealed the genetic features of tumors present in patients who initiate a successful antitumor immune response and derive clinical benefit from immune checkpoint blockade therapy versus non-responders.
authors.affiliation: Dept. of Medicine; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Snyder
authors.affiliation: Human Oncology and Pathogenesis Program; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Vladimir
authors.initials: V
authors.lastname: Makarov
authors.affiliation: Dept. of Medicine; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Hellmann
authors.affiliation: Division of Hematology/Oncology; New York Presbyterian/Columbia University Hospital ; New York, NY USA.
authors.forename: Naiyer
authors.initials: N
authors.lastname: Rizvi
authors.affiliation: Dept. of Medicine; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Taha
authors.initials: T
authors.lastname: Merghoub
authors.affiliation: Dept. of Medicine; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Jedd D
authors.initials: JD
authors.lastname: Wolchok
authors.affiliation: Human Oncology and Pathogenesis Program; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Timothy A
authors.initials: TA
authors.lastname: Chan
keywords: CTLA-4; PD-1; biomarkers; cancer; genomics; immunomonitoring; immunotherapy; mutation; new targets